Patients have previously been described who showed clinical signs and symptoms suggesting essential thrombocythemia (ET), but later transformed to polycythemia vera (PV). From a series of 344 patients with a sustained borderline to moderate erythrocytosis, 44 failed to conform initially with the diagnostic criteria of the WHO for PV, because of their low hemoglobin level. Twenty-three patients of this group presented with a thrombocytosis exceeding 600 × 109/l and therefore suggested ET, but later developed full-blown PV. For comparison we investigated also 164 patients with manifest PV, 90 patients with ET and 22 patients with reactive thrombocytosis (Th). The histopathology of initial PV was evaluated by stepwise discriminant analysis of 17 standardized features. Quantity and left shifting of erythro- and granulopoiesis, giant forms and naked nuclei of megakaryocytes, cellularity and reticulin fibers proved to exert a significant relevance concerning differentiation from true ET and Th. In conclusion, initial PV with thrombocytosis is characterized by a special pattern of BM histopathology. Therefore, so-called masked PV in patients with ET or simultaneous PVR-1 gene expression and endogeneous erythroid colony growth in ET patients are probably in keeping with initial PV mimicking ET.

Keywords:
Bone marrow histopathology, Discriminant analysis, Essential thrombocythemia, Polycythemia vera (initial) with thrombocytosis
1.
Pearson TC: Diagnosis and classification of erythrocytoses and thrombocytoses. Baillières Clin Haematol 1998;11:695–720.
2.
Michiels JJ, Thiele J: Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133–145.
3.
Berlin NI: Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339–351.
4.
Bilgrami S, Greenberg BR: Polycythemia rubra vera. Semin Oncol 1995;22:307–326.
5.
Pearson TC, Messinezy M: The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996;22(suppl 1):87–93.
6.
Spivak JL: Polycythemia vera: Myths, mechanisms, and management. Blood 2002;100:4272–4290.
7.
Murphy S, Peterson P, Iland H, Laszlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29–39.
8.
Murphy S: Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36:9–13.
9.
Ellis JT, Silver RT, Coleman M, Geller SA: The bone marrow in polycythemia vera. Semin Hematol 1975;12:433–444.
10.
Iland HJ, Laszlo J, Peterson P, Murphy S, Briere J, Weinfeld A, Rosenthal DS, Landaw SA, Ellis JT, Silverstein MN, Wasserman LR: Essential thrombocythemia: Clinical and laboratory characteristics at presentation. Trans Assoc Am Physicians 1983;96:165–174.
11.
Ellis JT, Peterson P, Geller SA, Rappaport H: Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144–155.
12.
Iland HJ, Laszlo J, Case DC Jr, Murphy S, Reichert TA, Tso CY, Wasserman LR: Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am J Hematol 1987;25:191–201.
13.
Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T: Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol 1999;78:219–222.
14.
Shih LY, Lee CT: Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994;83:744–748.
15.
Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G: Polycythaemia vera; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 32–38.
16.
Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G: Essential thrombocythaemia; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 39–41.
17.
Everitt BS, Dunn G: Applied Multivariate Data Analysis. London, Arnold, 2001.
18.
Pearson TC, Wetherley-Mein G: The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1979;1:189–196.
19.
Najean Y, Triebel F, Dresch C: Pure erythrocytosis: Reappraisal of a study of 51 cases. Am J Hematol 1981;10:129–136.
20.
Berglund S, Zettervall O: Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20–26.
21.
Messinezy M, Sawyer B, Westwood NB, Pearson TC: Idiopathic erythrocytosis – additional new study techniques suggest a heterogenous group. Eur J Haematol 1994;53:163–167.
22.
Messinezy M, Pearson TC: The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haematol 1999;21:309–316.
23.
Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A, Thiele J: Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma 2000;36:239–253.
24.
Westwood N, Dudley JM, Sawyer B, Messinezy M, Pearson TC: Primary polycythaemia: Diagnosis by non-conventional positive criteria. Eur J Haematol 1993;51:228–232.
25.
Messinezy M, Westwood NB, Woodcock SP, Strong RM, Pearson TC: Low serum erythropoietin – a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol 1995;17:217–220.
26.
Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F: The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003;139:470–475.
27.
Michiels JJ: Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. Hematol J 2004;5:93–102.
28.
Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1,213 patients followed for 20 years. Ann Intern Med 1995;123:656–664.
29.
Messinezy M, Pearson TC: Diagnosis of polycythaemia (editorial). J Clin Pathol 1998;51:1–2.
30.
Heimpel H: The present state of pathophysiology and therapeutic trials in polycythemia vera. Int J Hematol 1996;64:153–165.
31.
Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V: Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992;64:286–291.
32.
Georgii A, Buhr T, Buesche G, Kreft A, Choritz H: Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996;22(suppl 1):15–29.
33.
Thiele J, Kvasnicka HM: Chronic myeloproliferative disorders with thrombocythemia: A comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148–152.
34.
Thiele J, Kvasnicka HM, Fischer R: Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders – aids to diagnosis and classification. Ann Hematol 1999;78:495–506.
35.
Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL: PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004;83:364–370.
36.
Johansson P, Andreasson B, Safai-Kutti S, Wennstrom L, Palmqvist L, Ricksten A, Lindstedt G, Kutti J: The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia. Eur J Haematol 2003;70:358–362.
37.
Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC: Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869–1871.
38.
Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT: Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294–3301.
39.
Pahl HL: Molecular markers in myeloproliferative disorders: From classification to prognosis? Hematology 2003;8:199–209.
40.
Johansson P, Ricksten A, Wennstrom L, Palmqvist L, Kutti J, Andreasson B: Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol 2003;123:513–516.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.